BMY
Bristol-Myers Squibb Company NYSE Listed Jun 1, 1972$61.15
Pre-mkt
$61.12
-0.05%
Mkt Cap $124.9B
52w Low $42.52
71.3% of range
52w High $68.64
50d MA $64.25
200d MA $59.03
P/E (TTM)
13.5x
EV/EBITDA
9.4x
P/B
6.7x
Debt/Equity
2.5x
ROE
38.2%
P/FCF
9.7x
RSI (14)
12.70
ATR (14)
$1.20
Beta
0.27
50d MA
$64.25
200d MA
$59.03
Avg Volume
9.5M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Route 206 & Province Line Road · Princeton, NJ 08543 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BMO | 1.60 | 2.04 | +27.5% | 63.10 | -0.6% | +2.8% | +0.7% | +0.2% | +0.6% | -3.4% | — |
| Apr 30, 2026 | BMO | 1.42 | 1.58 | +11.3% | 57.59 | +0.2% | +5.2% | -3.9% | -1.4% | -0.8% | -0.7% | — |
| Feb 5, 2026 | BMO | 1.23 | 1.26 | +2.4% | 57.62 | +2.2% | +3.3% | +4.1% | -2.0% | +0.1% | -1.5% | — |
| Oct 30, 2025 | BMO | 1.52 | 1.63 | +7.2% | 42.60 | +1.6% | +7.1% | +1.0% | -0.1% | -0.9% | +1.9% | — |
| Jul 31, 2025 | BMO | 1.09 | 1.46 | +33.9% | 45.98 | -3.9% | -5.8% | +2.1% | +2.6% | +1.0% | -2.2% | — |
| Apr 24, 2025 | BMO | 1.49 | 1.80 | +20.8% | 48.52 | -1.2% | +0.4% | -1.6% | +1.2% | +1.6% | +2.0% | — |
| Feb 6, 2025 | BMO | 1.47 | 1.67 | +13.6% | 59.71 | -3.9% | -3.8% | -1.0% | -2.3% | +0.7% | +0.4% | — |
| Oct 31, 2024 | BMO | 1.49 | 1.80 | +20.8% | 52.66 | +2.2% | +5.9% | -2.6% | +2.1% | +0.9% | -1.2% | — |
| Jul 26, 2024 | BMO | 1.62 | 2.07 | +27.8% | 45.27 | +6.6% | +11.4% | -2.9% | +0.1% | -3.0% | +1.3% | — |
| Apr 25, 2024 | BMO | -4.41 | -4.40 | +0.2% | 48.86 | -3.0% | -8.5% | +0.3% | -0.5% | -1.6% | +0.6% | — |
| Feb 2, 2024 | BMO | 1.52 | 1.70 | +11.8% | 48.67 | +1.2% | +0.1% | -1.5% | +2.7% | -1.3% | +0.1% | — |
| Oct 26, 2023 | BMO | 1.76 | 2.00 | +13.6% | 56.61 | -4.7% | -6.4% | -3.7% | +0.5% | +0.5% | -0.5% | — |
| Jul 27, 2023 | BMO | 1.99 | 1.75 | -12.1% | 63.41 | -3.8% | -4.2% | +1.1% | +1.3% | -1.1% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5 | Argus | Upgrade | Hold → Buy | $75 | $65.89 | $64.81 | -1.6% | -3.4% | +0.8% | +0.9% | +0.2% | -1.9% |
| Apr 9 | BofA Securities | Maintains | Buy → Buy | — | $59.20 | $58.70 | -0.8% | +0.5% | -1.4% | -1.0% | +0.0% | -0.3% |
| Apr 8 | Guggenheim | Maintains | Buy → Buy | — | $57.67 | $58.01 | +0.6% | +2.7% | +0.5% | -1.4% | -1.0% | +0.0% |
| Apr 8 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $57.67 | $58.01 | +0.6% | +2.7% | +0.5% | -1.4% | -1.0% | +0.0% |
| Mar 17 | HSBC | Maintains | Hold → Hold | — | $59.71 | $60.13 | +0.7% | +0.0% | -0.6% | -2.1% | -1.1% | -0.8% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $60.66 | $60.97 | +0.5% | +1.0% | +0.6% | -0.5% | -0.3% | +2.1% |
| Feb 6 | Guggenheim | Maintains | Buy → Buy | — | $59.52 | $60.00 | +0.8% | +4.1% | -2.0% | +0.1% | -1.5% | -0.1% |
| Feb 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $59.52 | $60.00 | +0.8% | +4.1% | -2.0% | +0.1% | -1.5% | -0.1% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $59.52 | $60.00 | +0.8% | +4.1% | -2.0% | +0.1% | -1.5% | -0.1% |
| Jan 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $55.56 | $55.01 | -1.0% | -1.7% | -0.6% | +1.4% | +1.5% | +0.2% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $54.60 | $54.56 | -0.1% | +1.8% | -1.7% | -0.6% | +1.4% | +1.5% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $55.77 | $55.94 | +0.3% | +0.3% | +2.0% | -0.7% | -2.4% | -1.9% |
| Jan 9 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $55.90 | $55.72 | -0.3% | -0.1% | -0.2% | +0.3% | +2.0% | -0.7% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $54.42 | $55.24 | +1.5% | +4.2% | -1.4% | -0.1% | -0.2% | +0.3% |
| Jan 7 | UBS | Upgrade | Neutral → Buy | — | $54.42 | $55.24 | +1.5% | +4.2% | -1.4% | -0.1% | -0.2% | +0.3% |
| Dec 15 | BofA Securities | Upgrade | Neutral → Buy | — | $52.41 | $53.50 | +2.1% | +3.6% | -0.1% | -1.3% | -0.4% | +1.6% |
| Dec 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $51.20 | $52.27 | +2.1% | +2.4% | +3.6% | -0.1% | -1.3% | -0.4% |
| Dec 12 | Guggenheim | Upgrade | Neutral → Buy | — | $51.20 | $52.27 | +2.1% | +2.4% | +3.6% | -0.1% | -1.3% | -0.4% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $50.65 | $50.79 | +0.3% | +1.1% | -0.0% | +2.4% | +3.6% | -0.1% |
| Dec 4 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $50.96 | $50.80 | -0.3% | +1.9% | +0.4% | -0.9% | -2.0% | +1.1% |
| Dec 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $49.18 | $48.95 | -0.5% | -1.9% | +5.6% | +1.9% | +0.4% | -0.9% |
| Nov 17 | Citigroup | Maintains | Neutral → Neutral | — | $46.65 | $46.52 | -0.3% | +0.3% | +0.5% | -2.7% | +0.3% | +0.7% |
| Aug 1 | Citigroup | Maintains | Neutral → Neutral | — | $43.31 | $43.61 | +0.7% | +2.1% | +2.6% | +1.0% | -2.2% | +1.2% |
| Jul 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $47.66 | $47.45 | -0.4% | +1.8% | -3.4% | +1.0% | -1.9% | +1.6% |
| Apr 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $47.90 | $48.31 | +0.9% | +1.2% | +1.6% | +2.0% | -1.2% | +1.9% |
| Apr 23 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $49.82 | $47.63 | -4.4% | -2.6% | +0.4% | -1.6% | +1.2% | +1.6% |
| Apr 23 | Jefferies | Maintains | Buy → Buy | — | $49.82 | $47.63 | -4.4% | -2.6% | +0.4% | -1.6% | +1.2% | +1.6% |
| Apr 11 | UBS | Maintains | Neutral → Neutral | — | $50.46 | $50.47 | +0.0% | +0.5% | +1.2% | -2.6% | -1.3% | -0.3% |
| Apr 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $55.19 | $55.17 | -0.0% | -3.8% | +1.3% | -6.1% | +0.5% | +1.2% |
| Feb 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $57.42 | $57.46 | +0.1% | -1.0% | -2.3% | +0.7% | +0.4% | -0.3% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $59.95 | $58.87 | -1.8% | -1.4% | +1.0% | -3.8% | -1.0% | -2.3% |
| Jan 28 | Citigroup | Maintains | Neutral → Neutral | — | $60.62 | $60.28 | -0.6% | -3.1% | +0.5% | +0.2% | -0.3% | +1.7% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $57.14 | $56.98 | -0.3% | -0.6% | -1.7% | -0.8% | +0.7% | +0.3% |
| Dec 16 | Jefferies | Upgrade | Hold → Buy | — | $55.78 | $56.77 | +1.8% | +0.2% | +3.2% | -1.4% | -0.9% | +1.8% |
| Nov 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $59.82 | $59.82 | +0.0% | -1.3% | -1.0% | +0.2% | -3.9% | +1.0% |
| Nov 12 | BMO Capital | Maintains | Market Perform → Market Perform | — | $59.82 | $59.82 | +0.0% | -1.3% | -1.0% | +0.2% | -3.9% | +1.0% |
| Nov 12 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $59.82 | $59.82 | +0.0% | -1.3% | -1.0% | +0.2% | -3.9% | +1.0% |
| Nov 12 | Citigroup | Maintains | Neutral → Neutral | — | $59.82 | $59.82 | +0.0% | -1.3% | -1.0% | +0.2% | -3.9% | +1.0% |
| Nov 1 | BMO Capital | Maintains | Market Perform → Market Perform | — | $55.77 | $55.88 | +0.2% | -2.6% | +2.1% | +0.9% | -1.2% | -1.0% |
| Oct 25 | Citigroup | Downgrade | Buy → Neutral | — | $52.92 | $52.68 | -0.5% | -1.9% | +1.4% | -0.3% | +0.3% | +5.9% |
| Oct 18 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $53.18 | $53.26 | +0.2% | +0.1% | -2.1% | +1.2% | +0.6% | -0.3% |
| Oct 9 | UBS | Maintains | Neutral → Neutral | — | $52.48 | $52.25 | -0.4% | +0.6% | -0.8% | -0.4% | +0.9% | +0.2% |
| Oct 7 | Barclays | Maintains | Underweight → Underweight | — | $53.96 | $54.00 | +0.1% | -1.0% | -1.8% | +0.6% | -0.8% | -0.4% |
| Oct 7 | TD Cowen | Maintains | Hold → Hold | — | $53.96 | $54.00 | +0.1% | -1.0% | -1.8% | +0.6% | -0.8% | -0.4% |
| Sep 27 | BMO Capital | Maintains | Market Perform → Market Perform | — | $50.12 | $51.54 | +2.8% | +1.6% | +1.6% | +2.2% | +1.6% | +0.8% |
| Sep 23 | BMO Capital | Maintains | Market Perform → Market Perform | — | $49.41 | $49.56 | +0.3% | +1.2% | +1.9% | -1.9% | +0.3% | +1.6% |
| Sep 16 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $49.13 | $49.50 | +0.8% | +1.8% | -1.0% | +0.5% | -1.4% | +0.8% |
| Aug 28 | Jefferies | Maintains | Hold → Hold | — | $48.12 | $48.12 | +0.0% | +2.0% | +1.3% | +0.5% | +1.1% | -1.1% |
| Aug 22 | Barclays | Maintains | Underweight → Underweight | — | $48.44 | $48.57 | +0.3% | -1.7% | +1.0% | +0.3% | -0.2% | +2.0% |
| Aug 12 | TD Cowen | Maintains | Hold → Hold | — | $46.72 | $46.77 | +0.1% | +0.7% | +4.2% | -1.3% | +1.4% | +0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Massacesi CristianOff | EVP,Chief Med Offr,Head of Dev | Sell | 6,249 | $64.57 | $403K | 18,748 | -0.17% | -1.20% |
| Aug 25, 2026 | Holzer Phil MOff | SVP and Controller | Sell | 500 | $67.50 | $34K | 16,862 | -0.92% | +1.11% |
8-K · 8.01
!! High
Cytokinetics, Incorporated -- 8-K 8.01: Material Event / Announcement
Aug 13
8-K
Bristol-Myers Squibb Company -- 8-K Filing
May 8
8-K · 7.01
! Medium
BRISTOL MYERS SQUIBB CO -- 8-K 7.01: Regulation FD Disclosure
Bristol Myers Squibb disclosed Q1 2026 financial results and operational initiatives via investor presentation, providing transparency on company performance and strategic direction to shareholders.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Colgate-Palmolive's CEO is departing the board to lead Kraft Heinz, signaling leadership transition uncertainty at CL while potentially strengthening KHC's management team.
Mar 12
8-K · 5.02
!!! Very High
Protagenic Therapeutics, Inc.\new -- 8-K 5.02: Executive Change
Protagenic Therapeutics appoints Nichols as President, signaling potential leadership restructuring that could affect company strategy and investor confidence in the biotech firm's direction.
Mar 3
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Atrium Therapeutics appointed four new directors following its distribution from Bristol Myers Squibb, signaling completion of the planned spinoff and establishment of independent board governance.
Feb 27
8-K · 7.01
! Medium
Bristol-Myers Squibb Co. -- 8-K 7.01: Regulation FD Disclosure
Bristol-Myers Squibb disclosed financial and operating initiatives via a presentation posted ahead of its Q4 2025 earnings call, providing investors with strategic information concurrent with results announcement.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 180,384,994 | $10.4B | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 133,337,856 | $7.7B | Added | Jun 2026 |
| 3 | Jpmorgan Chase & Co | 92,475,194 | $5.5B | Added | Mar 2026 |
| 4 | Morgan Stanley | 56,697,274 | $3.1B | Added | Dec 2025 |
| 5 | Vanguard Portfolio Management Llc | 46,873,015 | $2.7B | Added | Jun 2026 |
| 6 | Norges Bank | 36,866,658 | $2.1B | New | Jun 2026 |
| 7 | Bank Of America Corp /de/ | 32,586,981 | $2.0B | Added | Mar 2026 |
| 8 | Aqr Capital Management Llc | 27,357,486 | $1.6B | Reduced | Jun 2026 |
| 9 | Primecap Management Co/ca/ | 24,985,149 | $1.5B | — | Mar 2026 |
| 10 | Northern Trust Corp | 24,758,771 | $1.5B | Added | Mar 2026 |
| 11 | Bank Of New York Mellon Corp | 23,301,337 | $1.4B | Reduced | Mar 2026 |
| 12 | Independent Franchise Partners Llp | 21,275,474 | $1.3B | Added | Mar 2026 |
| 13 | Pzena Investment Management Llc | 17,095,731 | $1.0B | Reduced | Mar 2026 |
| 14 | Invesco Ltd. | 15,509,999 | $941M | Reduced | Mar 2026 |
| 15 | Schroder Investment Management Group | 12,235,494 | $742M | Reduced | Mar 2026 |
| 16 | Acadian Asset Management Llc | 11,887,668 | $721M | Added | Mar 2026 |
| 17 | Royal Bank Of Canada | 10,958,702 | $665M | Reduced | Mar 2026 |
| 18 | Fmr Llc | 10,671,103 | $647M | Added | Mar 2026 |
| 19 | Two Sigma Investments, Lp | 10,085,383 | $581M | Reduced | Jun 2026 |
| 20 | Victory Capital Management Inc | 9,151,211 | $555M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$124.91B
Enterprise Value
$156.98B
P/E (TTM)
13.46x
Forward P/E
9.75x
PEG Ratio
-0.09x
P/B
6.74x
P/S
2.54x
P/FCF
9.72x
EV/EBITDA
9.42x
Shares Out
2.04B
Financials (TTM)
Revenue
$49.19B
Net Income
$9.28B
EBITDA
$16.67B
Free Cash Flow
$12.85B
Op Cash Flow
$14.16B
EPS Basic
$3.46
EPS Diluted
$4.54
EPS Forward
$6.27
Gross Margin
70.2%
Op Margin
28.3%
Net Margin
18.9%
Balance Sheet
Total Assets
$90.04B
Total Liab.
$71.53B
Total Equity
$18.51B
Cash
$10.67B
LT Debt
$42.85B
Book Value/Sh
$9.07
Debt/Equity
2.55x
Current Ratio
1.26
Quick Ratio
1.14
Returns & Growth
ROE
38.2%
ROA
7.8%
ROIC
13.9%
Rev Growth YoY
-0.2%
EPS Growth YoY
+178.5%
Price Returns
2W
-5.1%
1M
-9.1%
3M
+11.2%
6M
+6.6%
12M
+38.5%
Technicals
52W High
$68.64
52W Low
$42.52
50d MA
$64.25
200d MA
$59.03
RSI (14)
12.70
ATR (14)
$1.20
Beta
0.27
Avg Volume
9.5M
Dividends
Div Rate
$2.47
Div Yield
4.2%
Frequency
4
Ex-Div Date
Apr 2, 2026
Analyst Price Targets
Consensus
$62.00
High
$75.00
Low
$40.00
Median
$60.00
Data updated apr 24, 2026 10:16pm
· Source: financialmodelingprep.com